Olanzapine. Paliperidone. Paliperidone (trade name Invega), also known as 9-hydroxyrisperidone, is a dopamine antagonist and 5HT2A antagonist of the atypical antipsychotic class of medications. It is developed by Janssen Pharmaceutica. Invega is an extended release formulation of paliperidone that uses the OROS extended release system to allow for once-daily dosing. Paliperidone palmitate (trade name Invega Sustenna, named Xeplion in Europe) is a long-acting injectable formulation of paliperidone palmitoyl ester indicated for once-monthly injection after an initial titration period.
Paliperidone is used to treat mania and at lower doses as maintenance for bipolar disorder. It is also used for schizophrenia and schizoaffective disorder. Pharmacology[edit] Paliperidone is the primary active metabolite of the older antipsychotic risperidone.[1] While its specific mechanism of action is unknown, it is believed paliperidone and risperidone act via similar, if not identical, pathways. Adverse Effects[edit] - Hyperthermia. Biperiden. Biperiden is an antiparkinsonian agent[1] of the anticholinergic type.[2] The original brand name, which still exists and is manufactured by BASF/Knoll Pharma, is Akineton.
Generics are available worldwide. Pharmacokinetics[edit] The oral bioavailability is only 33 +/- 5% due to extensive first-pass metabolism. In young, healthy volunteers, peak plasma concentrations following a single oral 4 mg immediate-release dose are reached after 1.5 hours. Pharmacology[edit] Biperiden has an atropine-like blocking effect on all peripheral structures which are parasympathetic-innervated (e.g. cardiovascular and visceral organs). Uses[edit] Biperiden is used for the adjunctive treatment of all forms of Parkinson's disease and for reduced sweating in methadone users (postencephalitic, idiopathic, and arteriosclerotic). Biperiden is also commonly used to improve parkinsonian signs and symptoms related to antipsychotic drug therapy. Contraindications and cautions[edit] Special patient groups[edit]
Farmácias. Topiramate. Topiramate (brand name Topamax) is an anticonvulsant (antiepilepsy) drug. In late 2012, topiramate was approved by the United States Food and Drug Administration (FDA) in combination with phentermine for weight loss. The drug had previously been used off-label for this purpose. Topiramate was originally produced by Ortho-McNeil Neurologics and Noramco, Inc., both divisions of the Johnson & Johnson Corporation.
This medication was discovered in 1979 by Bruce E. Maryanoff and Joseph F. Medical uses[edit] Topiramate is used to treat epilepsy in children and adults, and it was originally used as an anticonvulsant. This drug has been used successfully as a treatment for alcoholism,[11] methamphetamine addiction, cocaine addiction,[12][13] obesity[14][15] and antipsychotic-induced weight gain.[16][17] This drug is also widely used to treat migraines due to the effect it has on the blood vessels in the brain. Adverse effects[edit] Adverse effects by incidence:[30][31][32][33] The U.S. Fluoxetine. Fluoxetine (also known by the tradenames Prozac, Sarafem, Ladose and Fontex, among others) is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class.
Fluoxetine was first documented in 1974 by scientists from Eli Lilly and Company.[6] It was approved by the U.S. Food and Drug Administration for the treatment of major depressive disorder in December 1987.[7] The fluoxetine patent expired in August 2001.[8] Despite the availability of newer agents, fluoxetine remains extremely popular. In 2010, over 24.4 million prescriptions for generic formulations of fluoxetine were filled in the United States alone,[11] making it the third most prescribed antidepressant after sertraline (SSRI; became generic in 2006) and citalopram (SSRI; became generic in 2003).[11] In 2011, 6 million prescriptions for fluoxetine were handed out in the UK.[12] Medical uses[edit] Depression[edit] Obsessive-Compulsive Disorder[edit] Panic Disorder[edit] Special populations[edit] Adverse effects[edit]